000130450 001__ 130450
000130450 005__ 20240125162930.0
000130450 0247_ $$2doi$$a10.1007/s00535-019-01619-0
000130450 0248_ $$2sideral$$a114509
000130450 037__ $$aART-2020-114509
000130450 041__ $$aeng
000130450 100__ $$aPuigvehí, Mark
000130450 245__ $$aImpact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients
000130450 260__ $$c2020
000130450 5203_ $$aBackground Direct-acting antivirals (DAAs) show highefficacy and safety in HCV–cirrhotic patients, but mostmaintain clinically significant portal hypertension aftersustainedvirologicalresponse(SVR).Non-invasiveBaveno and expanded-Baveno criteria can identifypatients without high-risk gastroesophageal varices (GEV)who have no need for endoscopic surveillance. However,data after SVR are scarce. We performed a multicenterstudy to evaluate SVR effects over GEV and diagnosticaccuracy of non-invasive criteria after SVR.
Methods HCV–cirrhotic patients receiving DAAs andbaseline endoscopic evaluation were included (November2014–October 2015). GEV were classified as low risk (LR-GEV) (\5 mm) or high risk (HR-GEV) (C5 mm or withrisk signs). Transient elastography (TE) and endoscopywere performed during follow-up.
Results SVR was achieved in 230 (93.1%) of 247included patients, 151 (65.7%) with endoscopic follow-up.Among 64/151 (42.4%) patients without baseline GEV, 8(12.5%) developed GEV after SVR. Among 50/151(33.1%) with baseline LR-GEV, 12 (24%) developed HR-GEV. Patients with GEV progression showed TEC25 kPabefore treatment (64.7%) orC20 kPa after SVR (66.7%).Only 6% of patients without GEV and LSM\25 kPabefore treatment, and 10% of those with baseline LSM\25 kPa and LSM\20 kPa after SVR showed GEVprogression after 36 months. The negative predictive valueof Baveno and expanded-Baveno criteria to exclude HR-GEV was maintained after SVR (100% and 90.7%,respectively).
Conclusions HCV–cirrhotic patients can develop HR-GEV after SVR. Surveillance is especially recommendedin those with GEV before antiviral treatment. Baveno andexpanded-Baveno criteria can be safely applied after SVR.
000130450 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130450 590__ $$a7.527$$b2020
000130450 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b17 / 92 = 0.185$$c2020$$dQ1$$eT1
000130450 592__ $$a2.33$$b2020
000130450 593__ $$aGastroenterology$$c2020$$dQ1
000130450 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130450 700__ $$aLondoño, María Carlota
000130450 700__ $$aTorras, Xavier
000130450 700__ $$0(orcid)0000-0003-4672-8083$$aLorente, Sara$$uUniversidad de Zaragoza
000130450 700__ $$aVergara, Mercedes
000130450 700__ $$aMorillas, Rosa María
000130450 700__ $$aMasnou, Helena
000130450 700__ $$0(orcid)0000-0002-7119-2244$$aSerrano, Trinidad$$uUniversidad de Zaragoza
000130450 700__ $$aMiquel, Mireia
000130450 700__ $$aGallego, Adolfo
000130450 700__ $$aLens, Sabela
000130450 700__ $$aCarrión, José Antonio
000130450 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130450 773__ $$g55, 2 (2020), 205-216$$pJ. gastroenterol.$$tJOURNAL OF GASTROENTEROLOGY$$x0944-1174
000130450 8564_ $$s914439$$uhttps://zaguan.unizar.es/record/130450/files/texto_completo.pdf$$yVersión publicada
000130450 8564_ $$s2369811$$uhttps://zaguan.unizar.es/record/130450/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130450 909CO $$ooai:zaguan.unizar.es:130450$$particulos$$pdriver
000130450 951__ $$a2024-01-25-15:11:40
000130450 980__ $$aARTICLE